{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T18:30:39Z","timestamp":1775759439718,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373476"],"award-info":[{"award-number":["82373476"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Basic Research Fund Project of Xi'an Jiaotong University","award":["xzy012022105"],"award-info":[{"award-number":["xzy012022105"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Kimura\u2019s disease (KD) is a rare chronic inflammatory condition characterized by nodules and lymphadenopathy in the head and neck region, exhibiting type II inflammation. Dupilumab is commonly used against type II inflammation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of dupilumab in KD patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The real-world study was conducted in a hospital in China.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Six male patients with a mean age of 24.50\u2009\u00b1\u200915.47\u2009years were treated with dupilumab following the same protocol as that for atopic dermatitis (AD). Clinical and laboratory indicators, such as maximum nodule diameter, blood eosinophil count, eosinophil percentage, and total serum IgE levels were assessed at baseline, Week 12 and Week 24. Adverse events were documented. Paired t-tests and one-way ANOVA were used for statistical analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The results showed significant reductions in the longest nodule diameter at Week 12 (P\u2009=\u20090.006) and Week 24 (P\u2009=\u20090.017) compared to baseline. Blood eosinophil count decreased by 57.95% (P\u2009=\u20090.024) at Week 12 and 90.59% (P\u2009=\u20090.030) at Week 24. Eosinophil percentage decreased by 58.44% (P\u2009=\u20090.026) at Week 12 and 89.37% (P\u2009=\u20090.013) at Week 24. Total serum IgE levels decreased by 78.02% (P\u2009=\u20090.040) at Week 12 and 89.55% (P\u2009=\u20090.031) at Week 24. The presence of AD did not affect the results. One patient experienced temporary facial erythema after 32\u2009weeks of treatment, which resolved with topical treatment. No other adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Dupilumab demonstrated effectiveness in treating KD without severe adverse events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/qjmed\/hcae048","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T15:47:50Z","timestamp":1710431270000},"page":"575-580","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of dupilumab in the treatment of Kimura\u2019s disease"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-1834","authenticated-orcid":false,"given":"Y L","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an 710004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y T","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an 710004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y F","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an 710004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X T","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an 710004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y M","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an 710004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H L","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University , Xi'an 710004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"key":"2024091118571054300_hcae048-B1","doi-asserted-by":"crossref","first-page":"1069102","DOI":"10.3389\/fmed.2022.1069102","article-title":"Kimura\u2019s disease: a clinicopathological study of 23 cases","volume":"9","author":"Lee","year":"2022","journal-title":"Front Med"},{"key":"2024091118571054300_hcae048-B2","doi-asserted-by":"crossref","first-page":"106591","DOI":"10.1016\/j.ijsu.2022.106591","article-title":"Treatment algorithm for Kimura\u2019s disease: a systematic review and meta-analysis of treatment modalities and prognostic predictors","volume":"100","author":"Lee","year":"2022","journal-title":"Int J Surg"},{"key":"2024091118571054300_hcae048-B3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.humimm.2013.06.001","article-title":"Increased CD45RO+ CD62L+ CD4+ T-cell subpopulation responsible for Th2 response in Kimura\u2019s disease","volume":"74","author":"Yamazaki","year":"2013","journal-title":"Hum Immunol"},{"key":"2024091118571054300_hcae048-B4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.anl.2010.03.011","article-title":"Increase of Th2 and Tc1 cells in patients with Kimura\u2019s disease","volume":"38","author":"Ohta","year":"2011","journal-title":"Auris Nasus Larynx"},{"key":"2024091118571054300_hcae048-B5","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1365-2133.1997.tb01562.x","article-title":"In vivo expression of IL-4, IL-5, IL-13 and IFN-gamma mRNAs in peripheral blood mononuclear cells and effect of cyclosporin A in a patient with Kimura\u2019s disease","volume":"137","author":"Katagiri","year":"1997","journal-title":"Br J Dermatol"},{"key":"2024091118571054300_hcae048-B6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5415\/apallergy.2017.7.4.221","article-title":"Basophils are increased and express increased levels of interleukin-4 in the parotid lesions of Kimura disease","volume":"7","author":"Nonaka","year":"2017","journal-title":"Asia Pac Allergy"},{"key":"2024091118571054300_hcae048-B7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2024091118571054300_hcae048-B8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1001\/jamadermatol.2021.5885","article-title":"Treatment of Kimura disease with dupilumab","volume":"158","author":"Teraki","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024091118571054300_hcae048-B9","doi-asserted-by":"crossref","first-page":"e15674","DOI":"10.1111\/dth.15674","article-title":"Dupilumab for recalcitrant Kimura disease","volume":"35","author":"Bellinato","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024091118571054300_hcae048-B10","doi-asserted-by":"crossref","first-page":"1084879","DOI":"10.3389\/fimmu.2022.1084879","article-title":"Successful treatment of dupilumab in Kimura disease independent of IgE: a case report with literature review","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"2024091118571054300_hcae048-B11","doi-asserted-by":"crossref","first-page":"e1084","DOI":"10.1002\/iid3.1084","article-title":"Clinical effects of dupilumab: a novel treatment for Kimura disease","volume":"11","author":"Shang","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"2024091118571054300_hcae048-B12","doi-asserted-by":"crossref","first-page":"1131963","DOI":"10.3389\/fped.2023.1131963","article-title":"Kimura disease in children: a report of 11 cases and review of the literature","volume":"11","author":"Mai","year":"2023","journal-title":"Front Pediatr"},{"key":"2024091118571054300_hcae048-B13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/qjmed\/hcz312","article-title":"Kimura\u2019s disease: effects of age on clinical presentation","volume":"113","author":"Kakehi","year":"2020","journal-title":"QJM"},{"key":"2024091118571054300_hcae048-B14","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MPH.0b013e3181fce3b0","article-title":"Kimura disease in children: a case report and a summary of the literature in chinese","volume":"33","author":"Xu","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"key":"2024091118571054300_hcae048-B15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2332\/allergolint.O-06-442","article-title":"Serum concentrations of eosinophil cationic protein and eosinophils of patients with Kimura\u2019s disease","volume":"56","author":"Ohta","year":"2007","journal-title":"Allergol Int"},{"key":"2024091118571054300_hcae048-B16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"2024091118571054300_hcae048-B17","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"2024091118571054300_hcae048-B18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2024091118571054300_hcae048-B19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.alit.2023.06.002","article-title":"Single-cell RNA sequencing of peripheral blood mononuclear cells from Kimura disease patient successfully treated with dupilumab","volume":"72","author":"Suga","year":"2023","journal-title":"Allergol Int"},{"key":"2024091118571054300_hcae048-B20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/jdv.19643","article-title":"Real-world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: results from the TREAT NL (TREatment of ATopic eczema, The Netherlands) registry","volume":"38","author":"Musters","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091118571054300_hcae048-B21","doi-asserted-by":"crossref","first-page":"e003135","DOI":"10.1136\/rmdopen-2023-003135","article-title":"Bilateral swelling of the salivary glands and sicca symptoms: an unusual differential diagnosis-Kimura\u2019s disease, a rare allergic condition with a high IgE serum level-a case report and review of the literature","volume":"9","author":"Braun","year":"2023","journal-title":"RMD Open"},{"key":"2024091118571054300_hcae048-B22","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.anl.2013.12.006","article-title":"Anti-IgE therapy to Kimura\u2019s disease: a pilot study","volume":"41","author":"Nonaka","year":"2014","journal-title":"Auris Nasus Larynx"},{"key":"2024091118571054300_hcae048-B23","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17021","article-title":"Anti-immunoglobulin E provides an additional therapy to conventional steroids for Kimura\u2019s disease","author":"Ao","year":"2023","journal-title":"J Dermatol"},{"key":"2024091118571054300_hcae048-B24","doi-asserted-by":"crossref","first-page":"S547","DOI":"10.1016\/S0091-6749(00)90059-9","article-title":"Molecular mechanisms of IgE regulation","volume":"105","author":"Bacharier","year":"2000","journal-title":"J Allergy Clin Immunol"},{"key":"2024091118571054300_hcae048-B25","doi-asserted-by":"crossref","first-page":"e90424","DOI":"10.1371\/journal.pone.0090424","article-title":"Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis","volume":"9","author":"Dema","year":"2014","journal-title":"PLoS One"},{"key":"2024091118571054300_hcae048-B26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2024091118571054300_hcae048-B27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"2024091118571054300_hcae048-B28"},{"key":"2024091118571054300_hcae048-B29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jdcr.2018.08.027","article-title":"The role of expanded series patch testing in identifying causality of residual facial dermatitis following initiation of dupilumab therapy","volume":"4","author":"Suresh","year":"2018","journal-title":"JAAD Case Rep"},{"key":"2024091118571054300_hcae048-B30","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jdcr.2019.07.020","article-title":"Dupilumab facial redness: positive effect of itraconazole","volume":"5","author":"de Beer","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2024091118571054300_hcae048-B31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"2024091118571054300_hcae048-B32","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-Severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcae048\/57116820\/hcae048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/117\/8\/575\/59089717\/hcae048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/117\/8\/575\/59089717\/hcae048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T23:11:11Z","timestamp":1726096271000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/117\/8\/575\/7630491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,3,16]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcae048","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"value":"1460-2725","type":"print"},{"value":"1460-2393","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,3,16]]}}}